Koninklijke Philips (NYSE:PHG) Rating Increased to Buy at Wall Street Zen

Koninklijke Philips (NYSE:PHG - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Saturday.

PHG has been the topic of several other reports. BNP Paribas raised Koninklijke Philips from a "neutral" rating to an "outperform" rating in a research note on Tuesday, February 25th. Sanford C. Bernstein raised Koninklijke Philips from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, March 18th. Finally, UBS Group raised Koninklijke Philips from a "neutral" rating to a "buy" rating in a research note on Thursday, February 20th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy".

Koninklijke Philips Price Performance

Shares of Koninklijke Philips stock opened at $23.47 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.23 and a quick ratio of 0.74. The business's 50 day simple moving average is $23.73 and its two-hundred day simple moving average is $25.41. The stock has a market capitalization of $22.06 billion, a P/E ratio of -27.94, a price-to-earnings-growth ratio of 0.82 and a beta of 0.76. Koninklijke Philips has a one year low of $21.48 and a one year high of $32.91.

Koninklijke Philips (NYSE:PHG - Get Free Report) last posted its earnings results on Tuesday, May 6th. The technology company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.13. Koninklijke Philips had a positive return on equity of 10.85% and a negative net margin of 3.88%. The firm had revenue of $4.31 billion for the quarter, compared to analysts' expectations of $4.10 billion. During the same period in the previous year, the firm earned $0.21 earnings per share. The business's revenue was down 1.0% compared to the same quarter last year. Analysts forecast that Koninklijke Philips will post 1.63 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Sei Investments Co. raised its stake in shares of Koninklijke Philips by 5.2% in the fourth quarter. Sei Investments Co. now owns 308,673 shares of the technology company's stock worth $7,816,000 after buying an additional 15,395 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in shares of Koninklijke Philips by 107.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 129,624 shares of the technology company's stock worth $3,282,000 after buying an additional 67,289 shares during the period. Raymond James Financial Inc. bought a new position in shares of Koninklijke Philips in the fourth quarter worth about $10,655,000. American Century Companies Inc. raised its stake in shares of Koninklijke Philips by 23.4% in the fourth quarter. American Century Companies Inc. now owns 295,158 shares of the technology company's stock worth $7,473,000 after buying an additional 55,911 shares during the period. Finally, Quantinno Capital Management LP raised its stake in shares of Koninklijke Philips by 71.1% in the fourth quarter. Quantinno Capital Management LP now owns 180,149 shares of the technology company's stock worth $4,561,000 after buying an additional 74,835 shares during the period. Institutional investors own 13.67% of the company's stock.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.